KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (ONC) Return on Capital Employed (2016 - 2025)

BeOne Medicines (ONC) has disclosed Return on Capital Employed for 8 consecutive years, with 0.37% as the latest value for Q4 2023.

  • On a quarterly basis, Return on Capital Employed fell 3.0% to 0.37% in Q4 2023 year-over-year; TTM through Dec 2023 was 0.37%, a 3.0% decrease, with the full-year FY2024 number at 0.18%, up 18.0% from a year prior.
  • Return on Capital Employed was 0.37% for Q4 2023 at BeOne Medicines, down from 0.35% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.13% in Q4 2021 to a low of 0.67% in Q4 2019.
  • A 5-year average of 0.38% and a median of 0.37% in 2020 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: tumbled -33bps in 2019, then grew 30bps in 2020.
  • BeOne Medicines' Return on Capital Employed stood at 0.67% in 2019, then skyrocketed by 45bps to 0.37% in 2020, then skyrocketed by 65bps to 0.13% in 2021, then plummeted by -171bps to 0.35% in 2022, then fell by -8bps to 0.37% in 2023.
  • Per Business Quant, the three most recent readings for ONC's Return on Capital Employed are 0.37% (Q4 2023), 0.35% (Q4 2022), and 0.13% (Q4 2021).